Antibody & Phage Display Shared Resource

抗体和噬菌体库共享资源-项目摘要/摘要 抗体和噬菌体展示共享资源提供了各种尖端技术的开发 抗体用作关键研究试剂。共享资源是由教师负责人阿德里安Krainer，博士， 和导演Johannes Yeh，Ph.D.共享资源与癌症中心成员合作， 癌症生物学中的基本和引人注目的问题，在研究领域包括：（1）理解 肿瘤微环境;（2）表面生物标志物的发现及其在肿瘤微环境中的差异表达 肿瘤发生;和（3）癌症中的受体信号传导。共享资源工作人员与科学家密切合作， 他们的实验需要的最佳方法，和专门的屏幕开发密切配合， 个别科学家。共享资源还测试和实施新技术、试剂和分析 与抗体产生的不同阶段相关的改进。目前， 共享资源包括通过啮齿动物脾细胞与永生化细胞系融合的杂交瘤开发， 从免疫的羊驼产生纳米抗体，以及从来自哺乳动物的B细胞直接克隆VH-VL结构域， 免疫啮齿类动物或羊驼，转化为表达质粒。酵母或噬菌体展示技术用于优化 在第一轮免疫和选择后鉴定的抗体的结合亲和力。库 在共享资源中产生的杂交瘤被维持，工作人员将从 这几行的要求。在上一个资助期间，12个癌症中心使用了该共享资源。 成员（32%），并为成员的七份出版物做出了贡献。新的抗体产生了 已经用于基因组学的试剂（例如，ChIP）、细胞分离（例如，FACS）和单细胞分析。 最后，最近开发的抗体目前正在研究用于潜在的诊断或治疗 在CSHL的癌症项目中发挥着至关重要的作用。

ANTIBODY & PHAGE DISPLAY SHARED RESOURCE - PROJECT SUMMARY/ABSTRACT The Antibody & Phage Display Shared Resource offers a variety of cutting-edge technologies to develop antibodies for use as key research reagents. The Shared Resource is led by Faculty Head Adrian Krainer, Ph.D, and Director Johannes Yeh, Ph.D. The Shared Resource collaborates with Cancer Center members to address fundamental and compelling questions in cancer biology, in research areas including: (1) The understanding of the tumor microenvironment; (2) The discovery of surface biomarkers and their differential expression during tumorigenesis; and (3) Receptor signaling in cancer. Shared Resource staff work closely with scientists to select the best approach for their experimental needs, and specialized screens are developed in close coodination with individual scientists. The Shared Resource also tests and implements new techniques, reagents, and assay improvements related to the different stages of antibody production. Technologies currently available in the Shared Resource include hybridoma development by fusion of rodent spleen cells with immortalized cell lines, generation of nanobodies from immunized alpacas, and direct cloning of the VH-VL domains from B cells from immunized rodents or alpacas into expression plasmids. Yeast or phage display techniques are used to optimize the binding affinities of antibodies identified after the first round of immunization and selection. A library of hybridomas generated in the Shared Resource is maintained, and staff will produce and purify antibodies from these lines on request. In the last funding period this Shared Resouce was used by twelve Cancer Center members (32%), and has contributed towards seven publications by members. Novel antibodies have generated reagents that have been used for genomics (e.g., ChIP), cell separation (e.g., FACS), and single-cell analysis. Finally, recently developed antibodies are currently being investigated for potential diagnostic or therapeutic applications by members, and are thus playing an essential role in cancer programs at CSHL.